N6F11

N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+ T cells[1][2][3][4].

Product Specifications

CAS Number

[851398-76-0]

UNSPSC

12352005

Target

Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/n6f11.html

Purity

98.37

Solubility

DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=CC=C(C2=CC3=C(C(NC(CCl)=N3)=O)S2)C=C1

Molecular Formula

C13H8Cl2N2OS

Molecular Weight

311.19

References & Citations

[1]Li J, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15 (720) :eadg3049.|[2]Liu J, et al. Cell type-specific induction of ferroptosis to boost antitumor immunity. Oncoimmunology. 2023 Nov 20;12 (1) :2282252. |[3]Shi TM, et al. Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer. J Med Chem. 2024 Feb 22;67 (4) :2238-2263.|[4]Liu J, et al. Adverse effects of ferroptotic therapy: mechanisms and management. Trends Cancer. 2024 May;10 (5) :417-429.